Study identifier:D6160C00057
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open-label, non-randomized study to evaluate the effect of tesaglitazar 1 mg once daily doses on ovulation suppression in healthy female volunteers on an combined oral contraceptive containing drospirenone and ethinyl estradiol
Diabetes Mellitus
Phase 1
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|